Immune checkpoint blockades (ICBs), including programmed death 1 (PD-1) inhibitors and cytotoxic T lymphocyte antigen-4 (CTLA-4) antibodies, have recently revolutionized the treatments for NSCLC and have emerged as promising therapeutic strategies for NSCLC patients [6, 7]. Here, CTLA4 is linked to non-small cell lung carcinoma.